2022
Léčba nemocnění asociovaného s imunoglobulinem IgG4
ADAM, Zdeněk, Milan DASTYCH, Aleš ČERMÁK, Martina DOUBKOVÁ, Šárka SKORKOVSKÁ et. al.Základní údaje
Originální název
Léčba nemocnění asociovaného s imunoglobulinem IgG4
Název anglicky
Therapy of immunoglonuline IgG4 related disease (IgG4-RD)
Autoři
ADAM, Zdeněk (203 Česká republika, garant, domácí), Milan DASTYCH (203 Česká republika, domácí), Aleš ČERMÁK (203 Česká republika, domácí), Martina DOUBKOVÁ (203 Česká republika, domácí), Šárka SKORKOVSKÁ (203 Česká republika, domácí), Luděk POUR (203 Česká republika, domácí), Zdeněk ŘEHÁK (203 Česká republika), Renata KOUKALOVÁ (203 Česká republika), Zuzana ADAMOVÁ (203 Česká republika), Martin ŠTORK (203 Česká republika, domácí), Marta KREJČÍ (203 Česká republika, domácí) a Ivanna BOICHUK (203 Česká republika, domácí)
Vydání
Vnitřní lékařství, Praha, Česká lékařská společnost J. E. Purkyně, 2022, 0042-773X
Další údaje
Jazyk
čeština
Typ výsledku
Článek v odborném periodiku
Obor
30203 Respiratory systems
Stát vydavatele
Česká republika
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Kód RIV
RIV/00216224:14110/22:00128161
Organizační jednotka
Lékařská fakulta
Klíčová slova česky
Abetacept; Dupilimab; Glucocorticoids; IgG4-related disease; Immunosuppressive agents; Rituximab; Sirolimus; Takrolimus
Klíčová slova anglicky
Abetacept; Dupilimab; Glucocorticoids; IgG4-related disease; Immunosuppressive agents; Rituximab; Sirolimus; Takrolimus
Štítky
Příznaky
Recenzováno
Změněno: 8. 2. 2023 14:33, Mgr. Tereza Miškechová
V originále
Immunoglobulin IgG4 related disease (IgG4-RD) is a heterogeneous disorder with multi-organ involvement recognised as a separate entity at the beginning of this century only. Evolving therapy is reviewed in this paper. Glucocorticoids are first choice drug but long administration of glucocorticoids is connected with many adverse effects. In case of combination glucocorticoids and immunosuppressive agents lower doses of glucocorticoids are needed, the response rate is higher and therapy is better tolerated. Rituximab is drug, that is possible use as monotherapy or in combination with glucocorticoids and immunosuppressive drugs. Only one study compared two immunosuporessive drugs, mycophenolate mofetil and cyclophosphamide. The response rated was similar but remissions were longer after glucocorticoids with cyclophosphamide then glucocorticoids with mycofenolat mofetil. No other comparative study of combination of various imunossupressive drugs with glucocorticoids was published. Rituximab has high number (90%) of response rate in monotherapy, but can be used in combination with glucocorticoids and immunosuppressives. Rituximab is now preferred and recommended for maintenance therapy administered in 6-month interval. In case of advanced disease, we prefer therefore combination of rituximab, cyclofosphamide and dexamethasone for initial therapy followed by maintenance with rituximab in 6 months interval. There are two new drugs under investigation abatacept and dupilimab with promising results. Although we have very intensive therapies for good results of therapy early diagnosis before irreversible fibrotic changes in IgG4-RD involved organs is still needed. © 2022, SOLEN s.r.o.. All rights reserved.
Anglicky
Immunoglobulin IgG4 related disease (IgG4-RD) is a heterogeneous disorder with multi-organ involvement recognised as a separate entity at the beginning of this century only. Evolving therapy is reviewed in this paper. Glucocorticoids are first choice drug but long administration of glucocorticoids is connected with many adverse effects. In case of combination glucocorticoids and immunosuppressive agents lower doses of glucocorticoids are needed, the response rate is higher and therapy is better tolerated. Rituximab is drug, that is possible use as monotherapy or in combination with glucocorticoids and immunosuppressive drugs. Only one study compared two immunosuporessive drugs, mycophenolate mofetil and cyclophosphamide. The response rated was similar but remissions were longer after glucocorticoids with cyclophosphamide then glucocorticoids with mycofenolat mofetil. No other comparative study of combination of various imunossupressive drugs with glucocorticoids was published. Rituximab has high number (90%) of response rate in monotherapy, but can be used in combination with glucocorticoids and immunosuppressives. Rituximab is now preferred and recommended for maintenance therapy administered in 6-month interval. In case of advanced disease, we prefer therefore combination of rituximab, cyclofosphamide and dexamethasone for initial therapy followed by maintenance with rituximab in 6 months interval. There are two new drugs under investigation abatacept and dupilimab with promising results. Although we have very intensive therapies for good results of therapy early diagnosis before irreversible fibrotic changes in IgG4-RD involved organs is still needed. © 2022, SOLEN s.r.o.. All rights reserved.